Abstract: Effective delivery is a critical issue in the use of conventional free drugs. Studies on the structure-function relationship of a therapeutic anti body-derived candidacidal decapeptide (killer peptide, KP) revealed its ability to spontaneously and reversibly self-assemble in an organized network of fibril-like structures. This process is catalyzed by 1,3-beta-glucans. While the self-assembled state may provide protection against proteases and the slow kinetic of dissociation assures a release of the active dimeric form over time, the beta-glucan affinity is responsible for targeted delivery. Thus, KP represents a novel paradigm of targeted autodelivering drugs.

Reversible self-assembly: A key feature for a new class of autodelivering therapeutic peptides / Pertinhez, Thelma; Conti, Stefania; Ferrari, Elena; Magliani, Valter; Spisni, Alberto; Polonelli, Luciano. - In: MOLECULAR PHARMACEUTICS. - ISSN 1543-8384. - 6:(2009), pp. 1036-1039. [10.1021/mp900024z]

Reversible self-assembly: A key feature for a new class of autodelivering therapeutic peptides

PERTINHEZ, Thelma;CONTI, Stefania;FERRARI, Elena;MAGLIANI, Valter;SPISNI, Alberto;POLONELLI, Luciano
2009-01-01

Abstract

Abstract: Effective delivery is a critical issue in the use of conventional free drugs. Studies on the structure-function relationship of a therapeutic anti body-derived candidacidal decapeptide (killer peptide, KP) revealed its ability to spontaneously and reversibly self-assemble in an organized network of fibril-like structures. This process is catalyzed by 1,3-beta-glucans. While the self-assembled state may provide protection against proteases and the slow kinetic of dissociation assures a release of the active dimeric form over time, the beta-glucan affinity is responsible for targeted delivery. Thus, KP represents a novel paradigm of targeted autodelivering drugs.
Reversible self-assembly: A key feature for a new class of autodelivering therapeutic peptides / Pertinhez, Thelma; Conti, Stefania; Ferrari, Elena; Magliani, Valter; Spisni, Alberto; Polonelli, Luciano. - In: MOLECULAR PHARMACEUTICS. - ISSN 1543-8384. - 6:(2009), pp. 1036-1039. [10.1021/mp900024z]
File in questo prodotto:
File Dimensione Formato  
09 KP_ mol pharm 2009.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 3.9 MB
Formato Adobe PDF
3.9 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2260925
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact